Bioelectronics Corp (BIEL)

[srinsocal]

You missed a few significant quotes

"The Company, working with its Chinese manufacturer, recently redesigned the manufacturing process to increase the reliability and shelf life of its current OTC product. The Company also did a proof-of-concept production run of its newly designed RecoveryRx product that is 50% more powerful and has a larger antenna thereby increasing the size of the surgical incision that can be treated. The plan is to test market these devices in the near future. (would a company with little cash invest in a redesign of its product if they did not anticipate demand for that product?)

"The Company is continuing talks with major distributors, both internationally and domestically. These talks are in different stages of progress, from discussing final approval and registration, to initial exploration of possible interest. Given the unique advantages of our product offerings, these discussions often take a long time, especially with major distributors that have multiple levels of management review." (This is a big improvement from the 12/25/23 Distribution Update which talked about KT forfeiting their exclusive US rights due to new management not actively promoting the KT Wave)

"Company representatives attended the Modern Musculoskeletal Care Symposium this past weekend in Columbus, Ohio. We were once again invited to exhibit and Dr. Berend spoke to the medical professionals in attendance about “Non Thermal Pulsed Shortwave Therapy for Pre and Post Op Pain” Our attendance at the show was predicated on the expectation that the use of RecoveryRx will expand through the OrthoAlliance (https://orthoalliance.com/) organization in the next few months." (Dr Berend is the Chief Medical Officer for the Ortho Alliance which has 180 doctors involved in orthopedic surgery)

"The Company is exploring entering into legal action against Mundi Pharma South East Asia for breach of contract. They signed a five-year contract in October of 2018 with BioElectronics Corporation, agreeing to purchase a minimum of approximately $14,000,000 worth of product from us over the next five years of the contract. However, they never completed the registration of the products into the five territories that we granted them exclusive distributorship and only took ownership of a small amount of the inventory. We have engaged both local counsel and counsel in Singapore, where any arbitration action would need to take place. The Company is actively seeking financial backing to support this legal action." (Mundi Pharma violated the terms of their contract with BIEL costing BIEL millions of dollars in revenue, BIEL is attempting to get compensation for this breach of contract via the courts)